On Monday CSX Corporation (NYSE:CSX)’s shares dwindled -0.24%, and closed at $33.24.
A commitment to employee development and diversity, combined with compriseently high performance in key business areas, earned CSX (CSX) a place as one of “America’s Best Employers,” according to a new survey published by Forbes magazine.
Michael J. Ward, chairman and chief executive officer stated that One of CSX’s core values is ‘People Make the Difference,’ and being recognized as one of the most highly recommended employers is a true honor and testament to our collective efforts.
CSX Corporation, together with its auxiliaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers.
Cognizant Technology Solutions Corp (NASDAQ:CTSH), declined -0.24%, and closed at $62.42.
Formerly on March 26, 2015 Senior executives across industries agree that new software “robots”, leveraging attributes such as machine learning, artificial intelligence, and effective use of big data, will unlock significant value within the next three to five years, according to a new study released by Cognizant (CTSH).
The study, conducted by Cognizant’s Center for the Future of Work, polled 537 senior business and technology decision-makers across multiple industry sectors, including financial services, insurance, healthcare, pharmaceutical, retail, hospitality, and technology. Respondents largely agreed that the benefits of intelligent process automation (IPA), and mining the resulting big data, can be characterized as providing money and meaning for their businesses — faster processing with fewer errors, unlimited scalability, and lower cost of ownership, along with the ability to make more timely business decisions through automation-enabled analytics.
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The corporation operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other.
At the end of Monday’s trade, Boston Scientific Corporation (NYSE:BSX), dipped -0.23%, and closed at $17.68.
Boston Scientific Corporation declares that it has signed a definitive contract to attain Xlumena, Inc., a venture-backed medical device corporation that develops, manufactures and sells minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract. The deal is predictable to close this week.
The Xlumena portfolio comprises the AXIOS™ and HOT AXIOS™ Stent and Delivery Systems. The AXIOS Stent and Delivery System has received U.S. Food and Drug Administration (FDA) clearance and is the world’s first stent designed for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg.
Biomed Realty Trust Inc (NYSE:BMR), dropped -0.22%, and closed at $22.50.
BioMed Realty Trust, Inc declared the signing of a 295,000 square foot lease at 675 West Kendall by Alnylam Pharmaceuticals in Cambridge, Massachusetts providing Alnylam with Class A laboratory and office space in the heart of Kendall Square.
Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. This growing life science corporation will occupy all the rentable space accessible on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
